Ziritaxestat Phase II Success Gives Galapagos Something To Cheer
Silver Lining After Filgotinib Woes
It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.
